Investor Presentation

December 2023

Justin Claeys, Vice President Investor Relations
Ann Hyllengren, Senior Director Investor Relations



Safe Harbor Statement

This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such acquisition or integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

This presentation includes GAAP and non-GAAP financial measures. In accordance with the requirements of SEC Regulation G, reconciliations between these two measures, if these slides are in hard copy, accompany the hard copy presentation or, if these slides are delivered electronically, are available on the Company's website at www.amgen.com within the Investors section.

AMGEN

FOUNDED
1980

GLOBAL HQ
Thousand Oaks, California, USA

EMPLOYEES
25,000+

 # OF PATIENTS REACHED
~10 million
ANNUALLY

R&D INVESTMENT
$4.4 billion
IN 2022

DONATIONS
$2.2 billion*
Through AMGEN SAFETY NET FOUNDATION IN 2022

MARKETS
~100

TOTAL REVENUE
$26.3 billion
IN 2022

Provided December 7, 2023, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update

*Valued at wholesale acquisition cost.

Our Products Reflect Our Commitment To Serving Patients Living With Serious Illness

Provided December 7, 2023, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update

AMGEN

Acute Lymphoblastic Leukemia

Rheumatoid Arthritis

Melanoma

Cancer

Severe Asthma

Non-small Cell Lung Cancer

Multiple Myeloma

Plaque Psoriasis

Crohn's Disease

Colorectal Cancer

ANCA-associated vasculitis

Non-Hodgkin's Lymphoma

Thyroid Eye Disease

Adjuvant Breast Cancer

Uncontrolled Gout

Heart Attack

Stroke

Obesity

Neuromyelitis optica spectrum disorder (NMOSD)

Migraine

chronic granulomatous disease

severe, malignant osteopetrosis

Chronic Heart Failure

Osteoporosis

Chronic Kidney Disease

Immune Thrombocytopenia

urea cycle disorders

nephropathic cystinosis

Secondary Hyperparathyroidism

AMGEN

Portfolio Of Leading Products With Significant Growth Potential

Inflammation

Otezla® (apremilast) 30mg tablets

Only oral systemic therapy for psoriasis with a broad indication

TEZSPIRE® (tezepelumab-ekko) Subcutaneous injection 210 mg

Launch off to strong start

Oncology

ONCE-DAILY ORAL LUMAKRAS™ (sotorasib) 120 mg tablets

Vectibix® (panitumumab) Injection for IV Infusion

Kyprolis® (carfilzomib) for injection

Nplate® romiplostim

XGEVA® (denosumab)

BLINCYTO® (blinatumomab) for injection 35 mcg single-dose vial

15% total volume growth*

General Medicine

Repatha® (evolocumab) injection 140 mg/mL

44% volume growth*

prolia® (denosumab) injection

7% volume growth*

EVENITY® (romosozumab-aqqg) injection 105 mg/1.17 mL

48% volume growth*

*Growth rates represent July 1, 2023 – September 30, 2023 vs. July 1, 2022 – September 30, 2022
EVENITY® is developed and commercialized in collaboration with UCB globally, as well as our collaboration partner Astellas in Japan. TEZSPIRE® is developed in collaboration with AstraZeneca.

AMGEN

Advancing **Pipeline Of Potentially First-in-class Molecules Targeting Serious Diseases**

INFLAMMATION

TEZSPIRE® approved in severe asthma and being studied for new indications including chronic obstructive pulmonary disease (COPD).

Rocatinlimab is an anti OX- 40 monochlonal antibody, being studied for the treatment of atopic dermatitis.

Efavaleukin alpha is being studied for the treatment of ulcerative colitis.

ONCOLOGY

BLINCYTO® approved in B-ALL, moving into earlier lines of treatment, exploring subcutaneous administration.

LUMAKRAS® approved in NSCLC and being studied for earlier line of therapy. Lumakras is also being studied for colorectal cancer (CR) and other tumors.

Xaluritamig is being studied for prostate cancer and is rapidly advancing based on encouraging Phase 1 data in mCRPC.

Tarlatamab is being studied for small-cell lung cancer (SCLC) and rapidly advancing following promising Phase 2 data.

AMG 193 is being studied for solid tumors with responses across six different MTAP-null solid tumors.

Bemarituzumab is being studied for gastric cancer and other tumors.

GENERAL MEDICINE

Repatha approved in hyperlipidemia and being studied for hypercholesterolemia in high-risk patients without prior MI or stroke.

Olpasiran is being studied for atherosclerotic cardiovascular disease in patients with high levels of Lp(a).

MariTide (formerly AMG 133) is a GLP-1 receptor agonist and GIPR antagonist, being studied for obesity. Topline data is anticipated from Phase 2 study in late 2024.

AMG 786 is being studied for obesity with data expected in 1H 2024.

Note: TEZSPIRE® is developed in collaboration with AstraZeneca. *Xaluritamig is being developed pursuant to a research collaboration with Xencor, Inc.*
B-ALL = B-cell precursor acute lymphoblastic leukemia, NSCLC = Non-Small Cell Lung Cancer, mCRPC =metastatic Castration Resistant Prostate Cancer, MTAP-null = methylthioadenosine phosphorylase deficiency, MI = myocardial infarction, Lp(a) = lipoprotein a.

A Few Comments From Our Q3 ’23 Earnings

- **Drove volume growth with our innovative brands and raised 2023 FY Guidance**
  - 11% volume growth achieved in Q3’23
- **Closed the Horizon Therapeutics transaction (Oct 6, 2023)**
  - Added Horizon’s rare disease medicines to our broad innovative portfolio
- **Expanded our international footprint by generating double-digit volume growth**
  - Generated 12% ex-U.S. volume growth (27% in Asia Pacific) in Q3’23
- **Accelerated our innovative pipeline**
  - Advancing obesity portfolio, encouraging new data from several oncology programs, rapidly enrolling multiple Ph3 studies
- **Delivered robust operating margins while investing ~$1B in internal innovation**
- **Increased dividend 10% year-over-year**

AMGEN

Industry- Leading Biosimilars Business Accretive To Long-term Growth



AT OUR BUSINESS REVIEW IN 2022, WE REPORTED OUR EXPECTATION FOR OUR 2030 BIOSIMILARS REVENUES TO MORE THAN DOUBLE 2021 REVENUES OF ~$2B

Provided December 7, 2023, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update

*Biosimilars to adalimumab (U.S. launch), eculizumab, ustekinumab, aflibercept, nivolumab, and additional pipeline molecules.**Growth rates represent July 1, 2023 – September 30, 2023 vs. July 1, 2022 – September 30, 2022. SOLIRIS is a registered trademark of Alexion Pharmaceuticals, Inc.; STELARA is a registered trademark of Janssen Biotech, Inc.; EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.; OPDIVO is a registered trademark of Bristol-Myers Squibb Company

AMGEN

We Are Investing in Our Research Capabilities

Investing for over a decade to prepare for the convergence of science and technology

- Leveraging **human data**
- Pursuing **multispecifics** to drug the "undruggable"
- Building leadership in generative biology - **Biologics NExT**

We Are Advancing Our ESG Agenda

We are on track to achieve our **2027 ambition**



Member of

Dow Jones Sustainability Indices

Powered by the S&P Global CSA

We are focused on **Diversity, Inclusion, and Belonging**



We are **serving patients in the low- and middle- income countries (LMICs)**

- ✓ Signed multiple partnership agreements for Health system strengthening and improving access for patients with cancer including breast cancer and pediatric patients with Burkitt Lymphoma.
- ✓ BLINCYTO® access program for pediatric patients with B-ALL.
- ✓ Pegfilgrastim added to WHO's EML and EMLc.

Provided December 7, 2023, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update

Note: Reductions take into account only verified reduction projections, do not take into account changes associated with the contraction or expansion of the Company and are measured against a 2019 baseline. B-ALL = B-cell precursor acute lymphoblastic leukemia; EML = Essential medicines list; EMLc = Essential Medicines list for children.

We Continue Returning Capital to Our Shareholders

We increased our dividends for the first nine months of 2023 by an additional **10%**



Provided December 7, 2023, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update

*Represents annualized dividend after September 2011 initiation.

We Are Focused On Executing Against Our Long-Term Objectives

- **Integrate and grow our new rare disease business**
- **Advance our first-in-class, best-in-class innovative pipeline**
- **Deliver strong financial performance; focused on volume growth**
- **Expand international footprint**
- **Continue industry leadership in biosimilars**